Latest From Luminex Corp.
Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.
This week’s roundup includes the appointment of Sanofi Genzyme’s executive vice president and various high-level appointments by companies including Recipharm, e-Therapeutics, Diplomat Pharmacy and Axovant.
No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
- Nanotechnology, Chips, etc.
In Vitro Diagnostics
- Chemistry, Immunoassay
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Luminex Corp.
- Senior Management
Nachum "Homi" Shamir, Pres. & CEO
Harris T Currie, VP, Fin. & Treasurer & CFO
Russell W Bradley, VP, Bus. Dev. & Strategic Planning
Jeremy Bridge-Cook, PhD, SVP, R&D
- Contact Info
Phone: (512) 219-8020
12212 Technology Blvd.
Austin, TX 78727
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.